Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein

International Journal of Cancer

Volumn 132, Issue 2, 2013, Pages 335-344

  Grasso, Felicia ^a   Negri, Donatella R M ^a   Mochi, Stefania ^a   Rossi, Alessandra ^a   Cesolini, Armando ^a   Giovannelli, Andrea ^a   Chiantore, Maria Vincenza ^a   Leone, Pasqualina ^a   Giorgi, Colomba ^a   Cara, Andrea ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

human papilloma virus; integrase; lentiviral vector; tumor; vaccine

Indexed keywords

CALRETICULIN; GREEN FLUORESCENT PROTEIN; INTEGRASE DEFECTIVE LENTIVIRUS VECTOR; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUTANT PROTEIN; PROTEIN E7; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TUMOR CELL; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS;

ANIMALS; CALRETICULIN; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTEGRASES; INTERFERON-GAMMA; KAPLAN-MEIER ESTIMATE; LENTIVIRUS; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT FUSION PROTEINS; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS; VACCINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869491956     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27676     Document Type: Article

References (40)

1. Giuliano AR, Anic G, Nyitray AG,. Epidemiology and pathology of HPV disease in males. Gynecol Oncol 2010; 117 (2 Suppl): S15-S19.
2. Stanley M,. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010; 117 (2 Suppl): S5-S10.
3. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307: 693-703.
4. Paavonen J, Jenkins D, Bosch FX, et al. HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-70.
5. Harrop R, John J, Carroll MW,. Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev 2006; 58: 931-47.
6. Dyson N, Howley PM, Münger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-7.
7. Münger K,. The role of human papillomaviruses in human cancers. Front Biosci 2002; 7: d641-d649.
8. Münger K, Phelps WC, Bubb V, et al. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989; 63: 4417-21.
9. Bischof O, Nacerddine K, Dejean A,. Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways. Mol Cell Biol 2005; 25: 1013-24.
10. zur Hausen H,. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
11. Trimble CL, Frazer IH,. Development of therapeutic HPV vaccines. Lancet Oncol 2009; 10: 975-80.
12. Santin AD, Bellone S, Gokden M, et al. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 2002; 346: 1752-3.
13. Bellone S, Pecorelli S, Cannon MJ, et al. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther 2007; 7: 1473-86.
14. Smahel M, Síma P, Ludvíková V, et al. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001; 281: 231-8.
15. Kim JW, Hung CF, Juang J, et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 2004; 11: 1011-18.
16. Gelebart P, Opas M, Michalak M,. Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum. Int J Biochem Cell Biol 2005; 37: 260-6.
17. Cheng WF, Hung CF, Chai CY, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001; 108: 669-78.
18. He Y, Munn D, Falo LD, Jr,. Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. Expert Rev Vaccines 2007; 6: 913-24.
19. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-19.
20. Cara A, Klotman ME,. Retroviral E-DNA: persistence and gene expression in non dividing immune cells. J Leukoc Biol 2006; 80: 1013-17.
21. Gillim-Ross L, Cara A, Klotman ME,. HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages. Viral Immunol 2005; 18: 190-6.
22. Negri DR, Bona R, Michelini Z, et al. Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells. Hum Gene Ther 2010; 21: 1029-35.
23. Negri DR, Michelini Z, Baroncelli S, et al. Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 2007; 15: 1716-23.
24. Coutant F, Frenkiel MP, Despres P, et al. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 2008; 3: e3973. doi:10.1371/journal.pone.0003973.
25. Hu B, Yang H, Dai B, et al. Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity. Hum Gene Ther 2009; 20: 1652-64.
26. Karwacz K, Mukherjee S, Apolonia L, et al. Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 2009; 83: 3094-103.
27. Michelini Z, Negri DR, Baroncelli S, et al. Development and use of SIV-based integrase defective lentiviral vector for immunization. Vaccine 2009; 27: 4622-9.
28. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-6.
29. Mochizuki H, Schwartz JP, Tanaka K, et al. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol 1998; 72: 8873-83.
30. Weiss S, König B, Morikawa Y, et al. Recombinant HIV-1 nucleocapsid protein p15 produced as a fusion protein with glutathione S-transferase in Escherichia coli mediates dimerization and enhances reverse transcription of retroviral RNA. Gene 1992; 121: 203-12.
31. Berger G, Durand S, Goujon C, et al. A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral vectors. Nat Protoc 2011; 6: 806-16.
32. Di Bonito P, Grasso F, Mochi S, et al. Anti-tumor CD8+ T cell immunityelicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology 2009; 395: 45-55.
33. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-9.
34. Negri DR, Michelini Z, Bona R, et al. Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opin Biol Ther 2011; 11: 739-50.
35. Negri DR, Michelini Z, Cara A,. Toward integrase defective lentiviral vectors for genetic immunization. Curr HIV Res 2010; 8: 274-81.
36. Hu B, Tai A, Wang P,. Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev 2011; 239: 45-61.
37. Lin K, Roosinovich E, Ma B, et al. Therapeutic HPV DNA vaccines. Immunol Res 2010; 47: 86-112.
38. Negri DR, Michelini Z, Baroncelli S, et al. Nonintegrating lentiviral vector-based vaccine efficiently induces functional and persistent CD8+ T cell responses in mice. J Biomed Biotechnol 2010; 2010: 534501 (7 pages). doi:10.1155/2010/534501.
39. Tseng CW, Hung CF, Alvarez RD, et al. Pretreatment with cisplatin enhances E7-specificCD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 2008; 14: 3185-92.
40. Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, et al. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 2007; 56: 997-1007.